Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company developing bispecific and trispecific immunotherapies for cancer, and its news flow reflects both scientific progress and capital markets activity. On this APVO news page, readers can follow company-issued updates and third-party coverage related to its immune-oncology pipeline and corporate developments.
Aptevo’s recent press releases highlight key milestones for mipletamig, its CD123 x CD3 T-cell engager in the RAINIER Phase 1b/2 trial for frontline acute myeloid leukemia. News items include reports of remission rates in early cohorts, safety observations such as the absence of cytokine release syndrome in frontline patients treated to date in reported cohorts, and presentations of data at major medical meetings like the American Society of Hematology (ASH).
Investors and clinicians can also track announcements on Aptevo’s expanding CD3-engaging portfolio, including bispecific candidates APVO442 (PSMA x CD3) for prostate cancer and APVO455 (Nectin-4 x CD3) for multiple solid tumor types, as well as trispecific candidates APVO451 and APVO452 that combine tumor targeting, T-cell activation, and CD40-mediated costimulation. News coverage often details preclinical data presented at scientific conferences such as the Society for Immunotherapy of Cancer (SITC).
In addition to R&D and clinical trial updates, APVO news includes quarterly financial results, descriptions of its cash runway, and disclosures about equity financings, including at-the-market offerings, registered direct offerings, and an equity line of credit structure. Regulatory and governance developments, such as reverse stock split implementation, Nasdaq compliance updates, and amendments to rights agreements, are also reported.
By reviewing the APVO news feed, readers can monitor how Aptevo communicates progress on its ADAPTIR and ADAPTIR-FLEX platform-derived candidates, its interactions with the capital markets, and its participation in scientific and industry conferences.
Aptevo Therapeutics (NASDAQ:APVO) announced breakthrough results from Cohort 3 of its Phase 1b/2 RAINIER trial evaluating mipletamig, a CD123 x CD3 bispecific antibody, in combination with venetoclax and azacitidine for newly diagnosed AML patients unfit for intensive chemotherapy.
Key highlights include a 100% remission rate (CR/CRi) at the highest dose level, with 40% of patients achieving MRD-negative status. Notably, the trial reported no dose-limiting toxicities or cytokine release syndrome, demonstrating a favorable safety profile. The trial is progressing with Cohort 4 now open for enrollment, and results are expected to be presented at a major medical conference in Q4.
Aptevo Therapeutics (NASDAQ:APVO) has expanded its oncology pipeline with two new trispecific candidates, APVO452 and APVO451, targeting prostate cancer and multiple solid tumors. These therapeutics leverage the company's proprietary ADAPTIR-FLEX platform and build upon clinical validation from mipletamig, their lead CD3-directed candidate.
APVO452 targets PSMA, CD3, and CD40 for prostate cancers, while APVO451 targets Nectin-4, CD3, and CD40 for various solid tumors. Both therapeutics are designed to simultaneously engage tumor antigens, activate T cells, and modulate immunosuppressive cells in the tumor microenvironment.
This expansion brings Aptevo's pipeline to eight bispecific and trispecific candidates, including five molecules utilizing their CRIS-7-derived CD3 pathway, positioning them as a leader in next-generation T cell engagers for both hematologic and solid tumor cancers.
Aptevo Therapeutics (Nasdaq:APVO) highlighted APVO442, its preclinical CD3-engaging bispecific antibody for prostate cancer treatment. Built on the company's ADAPTIR-FLEX platform, APVO442 uses the same CRIS-7-derived anti-CD3 binding domain as mipletamig but is specifically engineered for solid tumors.
The candidate is designed to selectively activate T cells within PSMA-expressing tumor microenvironment, potentially offering improved safety and maintained anti-tumor potency. Preclinical data demonstrates effective localization to prostate tumors while potentially sparing healthy tissue.
The targeted market is significant, with prostate cancer being the second most common cancer in men, representing over 300,000 new U.S. cases annually. The global treatment market, currently at $14 billion, is projected to reach $24 billion within the next decade.
Aptevo Therapeutics (Nasdaq:APVO) reported Q2 2025 financial results and significant clinical progress. The company's lead candidate mipletamig achieved an 85% remission rate in frontline AML patients across two trials. Aptevo expanded its CD3 bispecific portfolio by introducing APVO455, a Nectin-4 x CD3 bispecific targeting multiple solid tumors.
The company raised $15.9 million in Q2 2025, extending its cash runway into late Q4 2025, with an additional $25 million equity line of credit secured. Q2 financial results showed cash position of $9.4 million and a net loss of $6.2 million ($8.40 per share), compared to a $5.9 million loss in Q2 2024.
Aptevo Therapeutics (NASDAQ:APVO) has announced a 1-for-20 reverse stock split effective May 23, 2025, at 5:01 p.m. Eastern Time. Trading on the adjusted basis will begin on May 27, 2025. The reverse split will reduce outstanding shares from approximately 13.5 million to 0.7 million.
The measure, approved by stockholders on May 14, 2025, and finalized by the Board on May 21, 2025, is part of the company's strategy to maintain Nasdaq Capital Market listing compliance. The split will affect all outstanding shares, options, restricted stock units, and warrants. No fractional shares will be issued, with cash payments provided instead. The trading symbol "APVO" and the stock's par value of $0.001 will remain unchanged.